Just what is nutraceutical? Here’s the answer.
Nutraceuticals have been getting bad health and wellness rap for years.
Most of the chatter is about them not being “real.”. Doctors ignore them partly because they have not gone through any FDA-approved clinical trials, even as their patients rave about the health benefits they get from them.
Now, there’s a movement to team up nutraceuticals with psychedelics and apply the science developed around psychedelics to advance nutraceuticals as more credible health and wellness products.
The two have been vectoring toward each other for years.
What is a Neutraceutical?
According to one study, a nutraceutical product may be defined as a substance that has a physiological benefit or provides protection against chronic disease. “Nutraceutical” is a term derived from “nutrition” and “pharmaceutics.” The term is applied to products isolated from herbal products, dietary supplements (nutrients), specific diets, and processed foods such as cereals, soups, and beverages other than nutrition, which are also used as medicine.
Nutraceuticals may be used to improve health, delay the ageing process, prevent chronic diseases, increase life expectancy, or support the structure or function of the body. Due to their potential nutritional, safety, and therapeutic effects, they have recently received considerable interest.
Emphasis has been made on presenting herbal nutraceuticals as effective on hard curative disorders related to oxidative stress, including allergy, Alzheimer’s disease, cardiovascular, cancer, diabetes, eye, immune, inflammatory, and Parkinson’s diseases, as well as obesity.
And there it is—the overlap of nutraceuticals and psychedelics, as both appear to be working in the same direction as complementary solutions to the same human health and wellness issues.
One company that is taking a shot at upping the rigour of the clinical science of nutraceuticals while also working with psychedelic substance development is KGK Sciences, a subsidiary of Wellbeing Digital Sciences (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) that opened their new clinical research centre in London, Ontario, in September. “We knew that the dietary supplement industry needed to have clinical trials behind the products because it was a new industry back in 1997,” Najla Guthrie, president and CEO of Wellbeing Digital Sciences and KGK Sciences, told Psychedelia. “It was a cottage industry back then, starting with people who made all kinds of outrageous claims about products without any science behind them,” she said. “So are nutraceuticals needing the same type of scientific rigour that is required for psychedelics? I’d say no. People have been using them for centuries. We’re using the data to say, yes, this works for this. Or this is safe in these quantities that you’re proposing.” You’ve said that “psychedelics are different because of their psychotropic effects. “They need to go through the drug route for development, which has very stringent requirements of what needs to happen. You need the preclinical data; you need safety and toxicity data.”
Today, on the di “try supplement side, if it’s a new ingredient, for example, a dietary supplement maker also has to do some level of clinical trial work to verify the safety and efficacy of that product in a similar fashion to the trials of MDMA, psilocybin, and ibogaine, she said. “I think there’s “s“ mucrethere’s goingmucrethere’sgoinging on in the psychedelic space, and there’s a lot athere’snewnew products on the nutraceutical that we are working “on,” she said”. “Th“‘s a lot. “There are crossover and connections that we can make between the two, and a lot of innovation will get us further along.”
She said that “mmerely skeptical doctors have become more informed about nutraceuticals today, specifically those that have better science behind them and don’t.”. “Doctors had‘” been“ informed because it’s consumer-drit’st’s industry”,“ Guthrie says, “and” “the patient” ” comes in. Ssa’s’doci’m taking this. I’m taking this. Is that going to affect any of the medications that you have me o’?‘ and’ ‘I want to take these because I know they make me feel better‘.‘
That reworked scepticism from doctors is the same thing that is happening with psychedelics, she said. “I think what we ought to do for psychedelic drugs, though, is to make sure that we as an industry are responsible about how we bring these products to market, and we’re responsible for making sure that data-driven; they’re responsible for the policy that gets changed from a regulatory perspective is data-driven and scientifically backed“.“
The work of KG” “sciences is now about 70 per cent on nutraceuticals, with the rest of their development work in cannabis and psychedelics.” “Psychedelics is “an area that is going to skyrocket for u“,“ Guthrie said. “P” psilocybin
Researchers at KGK are currently doing a phase II clinical study with Halucenex, a life sciences company in Windsor, Nova Scotia, where they are going to look at the effects of a single dose of oral synthetic psilocybin medical products and the treatment of PTSD. The first patient is planned to be enrolled on October 11.
Another study that KGK is working on will examine the safety and efficacy of a microdose of oral synthetic psilocybin to treat cognitive and behavioural autism spectrum disorder symptoms in adults. “This has huge implications,” she said. T”e “p“c “initial “d”w “we’ve so far sfawe’veimalslsresults.”
The company” is looking at working with companies to combine selected nutraceuticals and psychedelics to address several different issues and enhance the mechanism of action of both.
KGK has other psychedelics studies for treating addiction, end-of-life, and chronic pain, she said.
More support for psychedelics and nutraceuticals working together comes from the American Herbal Products Association (AHPA), which chartered its own Psychedelic Plants and Fungi Committee in March to address issues related to the safe use and responsible commerce of lawfully marketed products derived from psychedelic plants and fungi. Elan Sudberg, CEO of Alkemist Labs, and the first committee’s sacommittee’sid thasacommittee’sidrgence of legal psychedelics being professionally used to address major mental health issues and research finding significant benefits in that context, “The” category “ory must be developed ” science and deliberation. Given that the AHPA’s mission is to promote responsible and sustainable promotion AHPA’smotetecommerce of herbal products to ensure that consumers have informed access to a wide variety of safe herbal goods is entirely appropriate for usAHPA’s’expertiseAHPA’slplpappropriaapprit’satete thatusAHPA’s’expertiseAHPA’slplp.”
Disclaimer: https://www.gr”en” a”ketreport.com/the-marriage-of-herbal-nutraceuticals-and-psychedelics/
Posted by: Times Of Hemp, TOH, #TOH, #TimesOfHemp, https://www.timesofhemp.com
